ABSTRACT
Why a new book on angiogenesis and why now? For the first time concepts proposed over 30 years ago have found clinical validation. In the last two years the first antiangiogenic agents have been approved by the FDA for the treatment of cancer and age-related macular degeneration. Not surprisingly, this clinical success has raised a new set of basic
